Enterome
enterome.com
Microbiome
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
PRESS RELEASE Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-f...
Read more
Report
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL) managed in the watch-and-wait setting EO2463-induc
Read more
Report
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics-induced CD8 T cell responses and clinical activity
EO2463 was well tolerated in monotherapy and in R2 combination therapy cohorts EO2463-induced CD8 T cell expansion significantly associated with clinical response across cohorts Data support development of EO2463-induced immune response as a predictive bi
Read more
Report
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics to treat "watch-and-wait" indolent non-Hodgkin lymphoma
Orphan Drug Designation confers regulatory, financial and strategic advantages EO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patients EO2463 has shown complementary efficacy to rituximab and other cance
Read more
Report
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cells Correlation established between EO2463-induced and B cell target-specific CD8 T-cell expansions and Lugano objective re
Read more
Report
TAP Virtual Panel (Blood Cancer Breakthroughs New Therapies for Patients)
The post TAP Virtual Panel (Blood Cancer Breakthroughs New Therapies for Patients) appeared first on Enterome.
Read more
Report
Enterome won't watch and wait - MedNous article
Download the article about Enterome in MedNous. (pdf format) The post Enterome won't watch and wait - MedNous article appeared first on Enterome.
Read more
Report
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
Mobasher held several executive roles in industry, most recently CMO at BeiGene IFLI contributed up to $9 million to Enterome's private funding round in 2025 Enterome has announced a series of encouraging clinical data for OncoMimics drug candidates in so
Read more
Report
Enterome presents strengthened interim Phase 2 results for lead OncoMimics immunotherapy EO2463 to treat follicular lymphoma at ASH
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) Of the 6 patients, 5 had a complete response (CR), 1 partial res
Read more
Report
Enterome OncoMimics immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastoma Data presented at 2025 SNO conference by lead investigator Paris, France - 2 DECEMBER 2025 (08:30 CET) Enterome, a clinical-stage company pionee
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Paris
France
HQ
Enterome
200-500 est. staff